NATIONAL UNIVERSITY OF SINGAPORE, YONG LOO LIN SCHOOL OF MEDICINE Multiple sclerosis (MS) is an autoimmune disease affecting the brain and spinal cord. In MS, the activated immune cells attack myelin, a protective layer surrounding nerve cells, which disrupts the transmission of nerve impulses along nerve cells. Over time, there is permanent damage or deterioration...
Tag: <span>Multiple sclerosis</span>
Post
Can MS Be Stopped Early in its Tracks?
Kelli Whitlock Burton October 31, 2022 Dimethyl fumarate (DMF) could delay — or even prevent — clinical symptoms in patients with radiologically isolated syndrome (RIS), the earliest detected pre-clinical phase of multiple sclerosis. Researchers found that DMF reduced the risk of a first acute or progressive event related to CNS demyelination by more than 80% compared with...
Post
Specialist explains why multiple sclerosis can be misdiagnosed
by Laura Hegwer, Rush University Medical Center Credit: Pixabay/CC0 Public Domain Every five minutes, someone in the world receives the life-changing news that they have multiple sclerosis, a chronic disease in which the immune system attacks the protective layer of the nerves and causes lesions, or scars, in the brain and spinal cord. If you’re...
Post
Bolstering the blood-CNS barrier could lead to new treatment approach for multiple sclerosis
by Jennifer Michalowski, University of Utah Health Sciences Graphical abstract. Credit: Neuron (2022). DOI: 10.1016/j.neuron.2022.07.015 Millions of people worldwide are living with multiple sclerosis (MS), a disease in which the immune system attacks cells in the central nervous system (CNS), causing unpredictable symptoms that can include tremors, weakness, vision problems, and fatigue. Treatments for MS aim to...
Post
Multiple sclerosis drug works in a surprising way
Drugs called interferon betas are common treatments for multiple sclerosis (MS), reducing relapses and slowing motor function decline. Interferon beta, a protein known to contain a zinc binding pocket, is thought to reduce proinflammatory molecules and even increase production of anti-inflammatory species in MS patients. But researchers now report in ACS Chemical Neuroscience that the molecule reduces the...
Post
Virtual reality technology could strengthen effects of traditional rehabilitation for multiple sclerosis
by Kessler Foundation Dr. Carly Wender supervises a research participant in a VR exercise training study at Kessler Foundation. Credit: Kessler Foundation/Jody Banks In a recent article, Kessler Foundation scientists advocated for the incorporation of virtual reality (VR) technology in cognitive rehabilitation research in multiple sclerosis (MS). They presented a conceptual framework supporting VR as...
Post
Turncoat T cells are at the core of multiple sclerosis and other inflammatory central nervous system disorders
by Delthia Ricks, Medical Xpress scRNAseq replicates. CD45.1+ P14 cells were adoptively transferred into adult CD45.2+ GP or GFAP:GP mice 24h before i.c. infection with rLCMV-GP33. At least six weeks later, mice were treated with antiCD8a depleting antibody or isotype control. One week after depletion, mice were treated with TAM i.p. for four consecutive days...
Post
Multiple sclerosis: Are there new treatments on the horizon?
Although multiple sclerosis (MS) affects millions of people worldwide, severely impacting their lives, to this day it remains unclear exactly what causes it, and there is currently no cure. What is the latest research on MS investigating, and what do the experts say about future research avenues? Where is the newest MS research headed to?...
Post
A new treatment reduces inflammation in multiple sclerosis mice models
UNIVERSITAT AUTONOMA DE BARCELONA A team led by the Institut de Neurociències at the Universitat Autònoma de Barcelona (INc-UAB) managed to reduce chronic inflammation associated with multiple sclerosis in mice thanks to the administration of a type of lipid that mediates inflammation. The team found that these types of mediator substances, responsible for resolving the...
Post
Small trial targeting Epstein-Barr infections shows promise as multiple sclerosis treatment
by Bob Yirka, Medical Xpress Demyelination by MS. The CD68 colored tissue shows several macrophages in the area of the lesion. Original scale 1:100. Credit: CC BY-SA 3.0 Marvin 101/Wikipedia A team of researchers at Atara Biotherapeutics has conducted a small Phase I clinical trial of a therapeutic called ATA188 that targets Epstein-Barr infections (EBV) as a treatment for...